Best of Big Technology: How Ozempic Changes Our Bodies, Minds, and Economy — With Johann Hari

Summary

Johann Hari makes the case that the obesity epidemic is primarily a food-environment problem, driven by processed and ultra-processed foods that blunt satiety and push overeating, rather than a failure of personal willpower. He explains GLP-1 drugs like Ozempic as synthetic, long-lasting versions of a natural fullness hormone, and says they can produce dramatic weight loss, reduce appetite for other substances, and potentially lower heart-disease risk. The conversation also explores uncertainty around brain and reward-system effects, including possible depression or suicidal ideation warnings, as well as rebound weight gain after discontinuation. Beyond medicine, Hari and Alex Kantrowitz discuss pricing disparities, compounding and shortage issues, and the possibility that widespread adoption could shift spending away from food and related sectors and into pharma, with implications for GDP and consumer behavior.

Notes

• Ozempic is framed as part of a broader GLP-1 wave affecting appetite, alcohol, nicotine, and the economy.
• The episode centers the obesity crisis as an interaction between biology and a changed food environment.
• Hari argues ultra-processed food is the primary driver of modern obesity growth.
• He uses the Cheesecake Park rat story to show that American-style food can override normal appetite regulation.
• The story is used to argue that food companies optimize for maximizing consumption, not satiety.
• Hari describes appetite control as a gut-hormone system, not a willpower issue.
• GLP-1 drugs are described as a synthetic copy that lasts far longer than endogenous GLP-1.
• Hari says the drugs dramatically changed his own intake and weight.
• He cites average weight-loss outcomes of 15% for Ozempic/Wegovy and 21% for Mounjaro.
• He says a future triple-agonist could average 24% weight loss, approaching bariatric surgery levels.
• More than 200 related drugs are in development because more than 40 gut hormones influence appetite.
• Hari links obesity and food-caused illness to a very large mortality burden.
• He claims obesity affects more than 200 diseases and complications.
• The discussion shifts to macro effects if a large share of consumers eat far less food.
• Hari says big food is already counter-positioning against GLP-1 adoption through body-positivity messaging.
• He expects tension between food companies and pharma as GLP-1 use expands.
• He predicts a consumption shift that could hit food retailers, airlines, and GDP.
• He says airlines may need less jet fuel if the population becomes thinner on average.
• He gives a 20% reduction estimate for heart disease, heart attack, or stroke risk.
• The drugs are presented as a huge public-health lever despite near-term economic disruption.
• Hari says British prices are far lower than U.S. prices.
• He frames U.S. pricing as a policy and lobbying problem rather than a manufacturing one.
• Compounded semaglutide is described as risky because it is not made in FDA labs.
• Hari warns that fake compounded products can cause severe injury, including coma.
• He says stopping the drugs usually leads to rapid weight regain.
• The episode treats durability after discontinuation as a central unresolved issue.
• Hari says diet and exercise fail to produce durable weight loss for about 85% of people.
• He argues weight gain raises a biological set point that resists later loss.
• Metabolic slowdown is presented as an evolved response to famine-like conditions.
• He says the modern abundance of calories is the opposite of the environment evolution prepared humans for.
• Hari says GLP-1 drugs may act on the brain and lower a biological set point.
• He says the mechanism is still debated and not fully understood.
• He raises the possibility of broader reward-system dampening beyond appetite alone.
• Some users report losing pleasure in eating, though Hari says his own pleasure increased.
• Hari says his emotional state did not immediately improve even as weight loss continued.
• He recounts a compulsive-eating trigger in Vegas that Ozempic interrupted.
• He says overeating on Ozempic can trigger vomiting, making binge behavior difficult to sustain.
• Hari compares GLP-1s to bariatric surgery to judge benefits and harms.
• He underscores that bariatric surgery has strong health benefits but meaningful psychological tradeoffs.
• The pediatric question is presented as the hardest ethical tradeoff in the discussion.
• He says obesity risk is severe enough that children should not be forced to choose between disease and medication.
• Japan is held up as a policy example of preventing childhood obesity through food regulation.